File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s12020-022-03281-8
- Scopus: eid_2-s2.0-85145499907
- WOS: WOS:000907082000001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: A prospective follow-up on thyroid function, thyroid autoimmunity and long COVID among 250 COVID-19 survivors
Title | A prospective follow-up on thyroid function, thyroid autoimmunity and long COVID among 250 COVID-19 survivors |
---|---|
Authors | |
Keywords | autoimmunity COVID-19 interferons post-acute COVID-19 syndrome thyroid function tests |
Issue Date | 3-Jan-2023 |
Publisher | Springer |
Citation | Endocrine, 2023, v. 80, n. 2, p. 380-391 How to Cite? |
Abstract | AbstractPurpose: We evaluated the evolution of thyroid function and autoimmunity among COVID-19 survivors over 6 months in relation to interferon beta-1b treatment and long COVID. Methods: We included COVID-19 survivors managed in a major COVID-19 centre between July 2020 and May 2021 who were reassessed three and/or six months after acute COVID-19. Thyroid function tests (TFTs) and anti-thyroid antibody titres were measured at acute COVID-19, 3-month and 6-month. Results: 250 COVID-19 survivors were included (mean age 52.7 years, 50.4% men). Persistent thyroid function abnormalities were more likely in those with abnormal TFTs in acute COVID-19 (P < 0.001). Among 51 patients with abnormal TFTs in acute COVID-19, 82.4% resolved upon follow-up. Of 199 patients with normal TFTs in acute COVID-19, only 4.5% had incident abnormal TFTs, more likely in interferon-treated patients (P = 0.044) and none clinically overt. Among 129 patients with complete 6-month follow-up for anti-thyroid antibody titres, there was no significant change overall, except for modest increase in anti-thyroid antibody titres among the 84 interferon-treated patients (P < 0.05 at both 3 months and 6 months). Long COVID occurred in 19.5% and 10.4% at 3 and 6 months respectively, where TFTs and anti-thyroid antibody titres were not predictive of its occurrence. Conclusion: Over 6 months, most abnormal TFTs in acute COVID-19 resolved, with no significant incident thyroid dysfunction. SARS-CoV-2 infection did not lead to change in thyroid autoimmunity, while interferon treatment was associated with modest increase in anti-thyroid antibody titres. Thyroid function and anti-thyroid antibodies did not play a significant role in long COVID. Keywords: COVID-19; autoimmunity; interferons; post-acute COVID-19 syndrome; thyroid function tests. |
Persistent Identifier | http://hdl.handle.net/10722/333949 |
ISSN | 2023 Impact Factor: 3.0 2023 SCImago Journal Rankings: 0.844 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lui, DTW | - |
dc.contributor.author | Tsoi, KH | - |
dc.contributor.author | Lee, CH | - |
dc.contributor.author | Cheung, CYY | - |
dc.contributor.author | Fong, CHY | - |
dc.contributor.author | Lee, ACH | - |
dc.contributor.author | Tam, AR | - |
dc.contributor.author | Pang, PLY | - |
dc.contributor.author | Ho, TY | - |
dc.contributor.author | Law, CY | - |
dc.contributor.author | Lam, CW | - |
dc.contributor.author | To, KKW | - |
dc.contributor.author | Chow, WS | - |
dc.contributor.author | Woo, YC | - |
dc.contributor.author | Hung, IFN | - |
dc.contributor.author | Tan, KCB | - |
dc.contributor.author | Lam, KSL | - |
dc.date.accessioned | 2023-10-10T03:14:50Z | - |
dc.date.available | 2023-10-10T03:14:50Z | - |
dc.date.issued | 2023-01-03 | - |
dc.identifier.citation | Endocrine, 2023, v. 80, n. 2, p. 380-391 | - |
dc.identifier.issn | 1355-008X | - |
dc.identifier.uri | http://hdl.handle.net/10722/333949 | - |
dc.description.abstract | <h2>Abstract</h2><p><strong>Purpose: </strong>We evaluated the evolution of thyroid function and autoimmunity among COVID-19 survivors over 6 months in relation to interferon beta-1b treatment and long COVID.</p><p><strong>Methods: </strong>We included COVID-19 survivors managed in a major COVID-19 centre between July 2020 and May 2021 who were reassessed three and/or six months after acute COVID-19. Thyroid function tests (TFTs) and anti-thyroid antibody titres were measured at acute COVID-19, 3-month and 6-month.</p><p><strong>Results: </strong>250 COVID-19 survivors were included (mean age 52.7 years, 50.4% men). Persistent thyroid function abnormalities were more likely in those with abnormal TFTs in acute COVID-19 (P < 0.001). Among 51 patients with abnormal TFTs in acute COVID-19, 82.4% resolved upon follow-up. Of 199 patients with normal TFTs in acute COVID-19, only 4.5% had incident abnormal TFTs, more likely in interferon-treated patients (P = 0.044) and none clinically overt. Among 129 patients with complete 6-month follow-up for anti-thyroid antibody titres, there was no significant change overall, except for modest increase in anti-thyroid antibody titres among the 84 interferon-treated patients (P < 0.05 at both 3 months and 6 months). Long COVID occurred in 19.5% and 10.4% at 3 and 6 months respectively, where TFTs and anti-thyroid antibody titres were not predictive of its occurrence.</p><p><strong>Conclusion: </strong>Over 6 months, most abnormal TFTs in acute COVID-19 resolved, with no significant incident thyroid dysfunction. SARS-CoV-2 infection did not lead to change in thyroid autoimmunity, while interferon treatment was associated with modest increase in anti-thyroid antibody titres. Thyroid function and anti-thyroid antibodies did not play a significant role in long COVID.</p><p><strong>Keywords: </strong>COVID-19; autoimmunity; interferons; post-acute COVID-19 syndrome; thyroid function tests.</p> | - |
dc.language | eng | - |
dc.publisher | Springer | - |
dc.relation.ispartof | Endocrine | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | autoimmunity | - |
dc.subject | COVID-19 | - |
dc.subject | interferons | - |
dc.subject | post-acute COVID-19 syndrome | - |
dc.subject | thyroid function tests | - |
dc.title | A prospective follow-up on thyroid function, thyroid autoimmunity and long COVID among 250 COVID-19 survivors | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s12020-022-03281-8 | - |
dc.identifier.scopus | eid_2-s2.0-85145499907 | - |
dc.identifier.volume | 80 | - |
dc.identifier.issue | 2 | - |
dc.identifier.spage | 380 | - |
dc.identifier.epage | 391 | - |
dc.identifier.eissn | 1559-0100 | - |
dc.identifier.isi | WOS:000907082000001 | - |
dc.identifier.issnl | 1355-008X | - |